ZA961073B - New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them - Google Patents

New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them

Info

Publication number
ZA961073B
ZA961073B ZA961073A ZA961073A ZA961073B ZA 961073 B ZA961073 B ZA 961073B ZA 961073 A ZA961073 A ZA 961073A ZA 961073 A ZA961073 A ZA 961073A ZA 961073 B ZA961073 B ZA 961073B
Authority
ZA
South Africa
Prior art keywords
contain
preparation
pharmaceutical compositions
transferase inhibitors
farnesyl transferase
Prior art date
Application number
ZA961073A
Inventor
Francois Clerc
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA961073B publication Critical patent/ZA961073B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA961073A 1995-02-09 1996-02-09 New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them ZA961073B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501490A FR2730492B1 (en) 1995-02-09 1995-02-09 NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
ZA961073B true ZA961073B (en) 1996-08-20

Family

ID=9475981

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961073A ZA961073B (en) 1995-02-09 1996-02-09 New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them

Country Status (16)

Country Link
EP (1) EP0808329A1 (en)
JP (1) JPH10513468A (en)
KR (1) KR19980702049A (en)
CN (1) CN1173873A (en)
AU (1) AU4722896A (en)
BR (1) BR9607318A (en)
CA (1) CA2210953A1 (en)
CZ (1) CZ249997A3 (en)
FI (1) FI973279A0 (en)
FR (1) FR2730492B1 (en)
NO (1) NO973607L (en)
PL (1) PL321710A1 (en)
SK (1) SK108897A3 (en)
TR (1) TR199700726T1 (en)
WO (1) WO1996024612A1 (en)
ZA (1) ZA961073B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730491B1 (en) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6015817A (en) * 1996-12-05 2000-01-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5932590A (en) * 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972966A (en) * 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2796943A1 (en) * 1999-07-30 2001-02-02 Aventis Pharma Sa BENZOXAZINN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE IN THERAPEUTICS
FR2796946A1 (en) * 1999-07-30 2001-02-02 Aventis Pharma Sa NOVEL 8-CARBONYL CHROMAN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (en) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
KR20100017866A (en) 2007-05-21 2010-02-16 노파르티스 아게 Csf-1r inhibitors, compositions, and methods of use
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibitors of akt activity
JP6073677B2 (en) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Fused heterocyclic compounds and their use
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
JP2013522292A (en) 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Indazole compounds and their use
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
ES2651347T3 (en) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Compositions and methods for cancer treatment
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN105849099B (en) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 Polycyclic inhibitors of cyclin dependent kinase 7(CDK7)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (en) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 Inhibitors of cyclin dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. Kdm5 inhibitors
CN118267470A (en) 2017-04-13 2024-07-02 赛罗帕私人有限公司 Anti-SIRP alpha antibodies
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
CA2072033A1 (en) * 1991-06-28 1992-12-29 Jackson B. Gibbs Non-substrate inhibitors of farnesyl protein transferase
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
WO1994026723A2 (en) * 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
US5439918A (en) * 1994-03-14 1995-08-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
WO1996024612A1 (en) 1996-08-15
SK108897A3 (en) 1997-12-10
CZ249997A3 (en) 1997-11-12
BR9607318A (en) 1997-12-30
NO973607D0 (en) 1997-08-05
CA2210953A1 (en) 1996-08-15
FI973279A (en) 1997-08-08
CN1173873A (en) 1998-02-18
AU4722896A (en) 1996-08-27
MX9705969A (en) 1997-11-29
NO973607L (en) 1997-08-05
EP0808329A1 (en) 1997-11-26
FI973279A0 (en) 1997-08-08
PL321710A1 (en) 1997-12-22
JPH10513468A (en) 1998-12-22
FR2730492B1 (en) 1997-03-14
FR2730492A1 (en) 1996-08-14
TR199700726T1 (en) 1998-01-21
KR19980702049A (en) 1998-07-15

Similar Documents

Publication Publication Date Title
ZA961072B (en) New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them
ZA961073B (en) New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them
ZA96258B (en) New farnesyl tranferase inhibitors their preparation and the pharmaceutical compositions which contain them
ZA965868B (en) Farnesyl transferase inhibitors their preparation and pharmaceutical compositions comprising them
ZA965750B (en) Farnesyl transferase inhibitors their preparation and pharmaceutical composition comprising them
NZ305254A (en) Farnesyl protein inhibitors and pharmaceutical compositions thereof
HUP9900185A3 (en) Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
HUP0001498A3 (en) Farnesyl transferase inhibiting 1,8-annelated imidazolyl-quinolinone derivatives, their intermediates, pharmaceutical compositions thereof and process for their preparation
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
IL135377A0 (en) Pharmaceutical compositions comprising mtp inhibitors
IL117860A0 (en) Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them
IL119466A0 (en) Thrombin inhibitors their preparation and pharmaceutical compositions containing them
IL122293A0 (en) Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them
HUP0203054A3 (en) Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use
ZA967827B (en) Pharmaceutical compositions
IL117554A0 (en) Imidazoquinazolines their preparation and pharmaceutical compositions containing them
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
EG24294A (en) Pharmaceutical compositions
IL117397A (en) Substituted naphthyl compounds and pharmaceutical compositions comprising them
GB9506382D0 (en) Pharmaceutical compositions
ZA954652B (en) New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them
GB9513972D0 (en) Pharmaceutical compositions
IL119371A0 (en) Sulfonylaminopyrimidines their preparation and pharmaceutical compositions containing them
IL118672A0 (en) Benzisothiazolyl-substituted aminomethylchromans their preparation and pharmaceutical compositions containing them